# Renal Cell Carcinoma: SBRT for Primary and Oligometastatic Disease ## Introduction Renal cell carcinoma (RCC) has traditionally been regarded as a radioresistant tumor when treated with conventional fractionation schemes. This perception has been challenged by the development of stereotactic body radiation therapy (SBRT), which delivers ablative doses per fraction. These high doses overcome the inherent radioresistance of RCC, resulting in high rates of local tumor control. Consequently, SBRT is increasingly utilized in managing both medically inoperable primary RCC and oligometastatic disease. ## Radiobiology of RCC and SBRT ### Conventional Radioresistance RCC typically exhibits a poor response to conventional radiation doses of 1.8 to 2.0 Gy per fraction. This resistance is partly driven by the VHL-HIF pathway, which promotes angiogenesis and may contribute to radiation resistance. Additionally, RCC cells possess a high capacity to repair sublethal DNA damage when exposed to conventional fractionation, further limiting the efficacy of standard radiotherapy. ### SBRT Overcomes Resistance SBRT employs ablative doses exceeding 8 to 10 Gy per fraction, which activate cell-killing mechanisms beyond direct DNA double-strand breaks. One such mechanism involves vascular endothelial damage at these high doses, leading to tumor ischemia. Another important pathway is ceramide-mediated apoptosis, which is triggered above a threshold dose of approximately 8 to 10 Gy. Furthermore, SBRT may induce immunogenic cell death, potentially enhancing systemic anti-tumor immune responses. ## SBRT for Primary RCC ### Indications SBRT is primarily indicated for patients who are medically inoperable due to factors such as advanced age, significant comorbidities, or having a solitary kidney with renal insufficiency. It is also considered for patients who refuse surgery or have tumors located in anatomically challenging sites that complicate partial nephrectomy. However, SBRT is not currently recommended as a replacement for surgery in operable patients. ### Technique The typical SBRT dose for primary RCC ranges from 40 to 50 Gy delivered in 3 to 5 fractions, with 40 Gy in 5 fractions being the most common regimen. Treatment requires body immobilization using devices with abdominal compression or active breathing control to minimize motion. Respiratory motion is assessed using 4D-CT, and either an internal target volume (ITV) or gating approach is employed for motion management. Daily cone-beam CT (CBCT) with soft tissue matching ensures precise image guidance. Planning target volume (PTV) margins generally range from 3 to 5 mm, depending on the motion management strategy used. ### Outcomes SBRT achieves excellent local control rates of 90 to 98% at 2 to 3 years. The International Radiosurgery Consortium of the Kidney (IROCK) multi-institutional analysis reported local control rates of 97.8% at 2 years and 97.1% at 4 years. Renal function preservation is generally favorable, with a mean decline in glomerular filtration rate (GFR) of approximately 10 to 15%. Overall survival in these patients is more influenced by comorbidities than by cancer-related mortality. ![SBRT treatment plan for primary renal cell carcinoma with dose color wash](images/renal-sbrt-plan.jpg) ## Dose Constraints for Renal SBRT When delivering a 5-fraction SBRT regimen, critical structures must be carefully protected. For the contralateral kidney, the mean dose should be kept below 10 Gy, and the volume receiving 17.5 Gy (V17.5 Gy) should be less than 33%. Preservation of functional parenchyma in the ipsilateral remaining kidney is essential. The duodenum and small bowel should receive less than 0.5 cc volume at 30 Gy (V30 Gy) and a maximum dose (Dmax) below 35 Gy. The stomach should also have a V30 Gy under 0.5 cc. The spinal cord must be limited to a maximum dose of less than 25 Gy. For right-sided tumors, the liver mean dose should remain below 15 Gy, with uninvolved liver volume receiving 15 Gy (V15 Gy) under 700 cc. ## SBRT for Oligometastatic RCC ### Clinical Rationale RCC is well recognized for its oligometastatic phenotype, where patients present with a limited number of metastatic sites amenable to local therapy. Historically, metastasectomy has been performed with curative intent for RCC metastases. SBRT provides a non-invasive alternative for patients who are poor surgical candidates or have multiple oligometastatic lesions. ### Common Metastatic Sites Treated The lung is the most common metastatic site treated with SBRT, achieving excellent local control rates exceeding 90%. Bone metastases treated with SBRT benefit from durable pain relief and local control. Adrenal metastases also respond well to ablative doses, yielding high local control. Lymph nodes exhibiting oligoprogressive disease can be effectively treated with SBRT. For brain metastases, stereotactic radiosurgery (SRS) is preferred over whole brain radiation therapy. ### Outcomes for Oligometastatic SBRT Local control rates across metastatic sites range from 85 to 95%. SBRT may delay the initiation of systemic therapy and has the potential to prolong disease-free intervals in selected patients. ![CT-guided SBRT for oligometastatic renal cell carcinoma to the lung](images/rcc-lung-sbrt.jpg) ## SBRT in Combination with Systemic Therapy ### Tyrosine Kinase Inhibitors (TKIs) Concurrent administration of TKIs with SBRT requires caution due to the potential for increased toxicity, including hemorrhage and wound healing complications. It is generally recommended to hold TKIs for one week before and after SBRT, although decisions should be individualized based on patient factors. ### Immune Checkpoint Inhibitors (ICIs) RCC is highly responsive to immunotherapy agents such as nivolumab, ipilimumab, and pembrolizumab combinations. Combining SBRT with ICIs may enhance abscopal responses, where localized radiation induces systemic anti-tumor effects. Active clinical trials are investigating the optimal sequencing and safety of SBRT combined with ICIs. Preliminary data suggest that toxicity is acceptable with either concurrent or sequential treatment approaches. ## Emerging Directions Emerging strategies include cytoreductive SBRT targeting the primary tumor in metastatic RCC, analogous to cytoreductive nephrectomy. SBRT is also being applied to oligoprogressive sites while patients continue systemic therapy. Prospective randomized trials are underway comparing SBRT with observation for oligometastatic RCC. Additionally, biomarker-driven approaches aim to select patients most likely to benefit from local ablative therapy. ![MRI-guided adaptive SBRT for renal tumor adjacent to bowel](images/mri-guided-renal-sbrt.jpg) ## Key Clinical Pearls The radioresistance of RCC is effectively overcome by the ablative doses used in SBRT, which activate vascular damage and ceramide-mediated apoptosis pathways in addition to causing direct DNA damage. In medically inoperable primary RCC, SBRT achieves local control rates exceeding 95% at two years while preserving renal function acceptably. The oligometastatic phenotype of RCC is well established, and SBRT to metastatic sites provides durable local control and can delay the need for systemic therapy. When combining SBRT with tyrosine kinase inhibitors or immune checkpoint inhibitors, careful coordination is necessary due to the potential for overlapping toxicities. ## References 1. Siva S, Louie AV, Warner A, et al. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Consortium of the Kidney (IROCK). *Cancer*. 2018;124(5):934-942. 2. Tang C, Msaouel P, Hara K, et al. Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial. *Lancet Oncol*. 2021;22(12):1732-1739. 3. Correa RJM, Louie AV, Staehler M, et al. Stereotactic radiotherapy as a treatment option for renal tumors in the solitary kidney. *J Urol*. 2019;201(4):750-757. 4. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. Version 2.2025.